Open this publication in new window or tab >>Show others...
2024 (English)In: BMC Cancer, E-ISSN 1471-2407, Vol. 24, no 1, article id 311Article, review/survey (Refereed) Published
Abstract [en]
Objectives: For drugs reimbursed with limited evidence of patient benefits, confirmatory evidence of overall survival (OS) and quality of life (QoL) benefits is important. For QoL data to serve as valuable input to patients and decision-makers, it must be measured and analyzed using appropriate methods. We aimed to assess the measurement and analyses of post-reimbursement QoL data for cancer drugs introduced in Swedish healthcare with limited evidence at the time of reimbursement. Methods: We reviewed any published post-reimbursement trial data on QoL for cancer drugs reimbursed in Sweden between 2010 and 2020 with limited evidence of improvement in QoL and OS benefits at the time of reimbursement. We extracted information on the instruments used, frequency of measurement, extent of missing data, statistical approaches, and the use of pre-registration and study protocols. Results: Out of 22 drugs satisfying our inclusion criteria, we identified published QoL data for 12 drugs in 22 studies covering multiple cancer types. The most frequently used QoL instruments were EORTC QLQ-C30 and EQ-5D-3/5L. We identified three areas needing improvement in QoL measurement and analysis: (i) motivation for the frequency of measurements, (ii) handling of the substantial missing data problem, and (iii) inclusion and adherence to QoL analyses in clinical trial pre-registration and study protocols. Conclusions: Our review shows that the measurements and analysis of QoL data in our sample of cancer trials covering drugs initially reimbursed without any confirmed QoL or OS evidence have significant room for improvement. The increasing use of QoL assessments must be accompanied by a stricter adherence to best-practice guidelines to provide valuable input to patients and decision-makers.
Place, publisher, year, edition, pages
BioMed Central (BMC), 2024
Keywords
Cancer, Health-related quality of life, Patient-reported outcomes, Quality assessment, Randomized controlled trials
National Category
Cancer and Oncology Health Care Service and Management, Health Policy and Services and Health Economy Surgery
Research subject
Economics
Identifiers
urn:nbn:se:kau:diva-99184 (URN)10.1186/s12885-024-12045-8 (DOI)001180646300008 ()38448848 (PubMedID)2-s2.0-85186928709 (Scopus ID)
Funder
Jan Wallander and Tom Hedelius Foundation and Tore Browaldh Foundation, P21-0018
2024-04-042024-04-042024-07-04Bibliographically approved